Semiconductor stocks have come under pressure as investors question whether the AI boom can continue supporting the sector's lofty valuations. ...
U.S. stocks were mixed on Monday after an early rally faded, as a steep semiconductor sell-off offset relief from falling oil prices and easing tensions between the United States and ...
SpaceX (SPCX) has gone from one of Wall Street's most buzzed-about listings to one of its biggest casualties, with shares losing more than half their value from their post-listing peak. ...
U.S. stocks traded higher on Friday as investors looked past another busy round of corporate earnings and welcomed a pullback in oil prices after this week's steep rally. ...
Bitcoin (BTC) has steadied after months of volatility, fueling debate across the crypto industry over whether the market has finally established a bottom or if further downside remains ahead. ...
U.S. stocks fell sharply on Thursday as disappointing earnings from Alphabet and Tesla sparked a broad technology sell-off, while surging oil prices and escalating tensions in the Middle East added ...
Super Micro Computer (SMCI) surged on Wednesday after it delivered an upbeat business update that soothed investor concerns about profitability and highlighted continued strength in demand for AI infrastructure. ...
U.S. stocks were mixed Wednesday as investors paused ahead of earnings from Alphabet and Tesla, the first two Magnificent Seven companies to report this earnings season. ...
U.S. stocks traded higher on Tuesday as a rebound in semiconductor shares helped lift the broader market despite ongoing geopolitical tensions in the Middle East and fresh trade concerns. ...
Semiconductor stocks remained under intense pressure on Friday as investors continued pulling back from one of the market's strongest-performing sectors, extending a steep correction fueled by valuation concerns, rising AI ...
U.S. stocks were in the red on Friday as a steep sell-off in semiconductor shares overshadowed encouraging inflation data and improving consumer sentiment. ...
Eli Lilly (LLY) is making another significant push beyond its blockbuster diabetes and obesity franchises, announcing an agreement to acquire clinical-stage biotech AtaiBeckley in a deal valued at up to ...